EMA on injection with AstraZeneca: benefits outweigh risk

No vaccine is as much discussed and scrutinized as AstraZeneca. Today EMA ruled that there are indeed side effects, but that the benefits of the vaccine are greater. So, if it is up to EMA.

Indeed, serious blood problems should be considered as very rare side effects of AstraZeneca’s corona vaccine, the European Medicines Agency (EMA) has ruled. However, the benefits of the vaccine outweigh the very low risk of blood clots (thrombosis) and low platelet count (thrombocytopenia), conclude investigators who have examined all reports.

EMA about AstraZeneca

EMA reiterates that Covid-19 can lead to hospitalization, can kill people and that AstraZeneca’s vaccine can prevent that. Corona vaccines are also scarce.

In Great Britain people are being urged to get vaccinated with AstraZeneca and not to be put off by the reports, in many other countries the injection with this vaccine has been stopped.

Experts on blood clotting

The experts from the safety committee see a “possible link” between the vaccine and the serious blood disorders. They examined 86 reports, 18 of which were fatal, out of a total of some 25 million people who received the vaccine. By way of comparison: the RIVM estimates that in the Netherlands between 1 percent and 1.3 percent of all corona infections is fatal. In our country, the rare combination of thrombosis and low platelet count has been reported five times so far. One woman died of a pulmonary embolism as a result.

Death after injection

Most of the other people who died in the two weeks after the injection were also women. Most were younger than 60 years old. However, based on the current evidence, EMA cannot confirm that there are ‘specific risk factors’ such as age or gender.

The rare combined clinical picture may stem from an immune response, EMA says. A similar reaction is sometimes caused by a thrombosis drug, heparin.

Rude Erdogan does not give EU leader von der Leyen a seat and her reaction?

Spotted a mistake? Mail us. We are grateful to you.

Reply to article:

EMA on injection with AstraZeneca: benefits outweigh risk

Leave a Reply

Your email address will not be published. Required fields are marked *